Keystone Heart

What Keystone Heart does

Keystone Heart is a privately held Israeli medical device company founded in 2004 and headquartered in Herzliya, Israel. It develops cerebral embolic protection devices intended to capture and remove debris dislodged during cardiovascular procedures — most notably transcatheter aortic valve replacement (TAVR) and other structural heart interventions — to reduce the risk of periprocedural stroke. The company's flagship product line addresses a specific clinical gap in structural heart procedures, sold into hospital catheterization laboratories and hybrid operating rooms performing these interventions.

The company has pursued a focused, niche-device commercial strategy supported by a single disclosed institutional funding round — a $14 million Series 2 in May 2014 led by OrbiMed with participation from Caesarea Medical Electronics. In June 2020, Keystone Heart acquired 510 Kardiac Devices for an undisclosed sum, signaling an intent to broaden its cardiac device portfolio beyond cerebral protection. The company operates with a small team (11–50 employees) and no disclosed manufacturing, distribution, or pricing model.

Public visibility into Keystone Heart is currently limited: the corporate website resolves to a default cPanel page, indicating either a hosting/server issue or that the domain has been deprioritized. No customer logos, revenue figures, headcount trend, recent product launches, regulatory milestones, or strategic partnerships beyond the 2014 funding and 2020 acquisition are disclosed in the available data. Leadership consists of Shuki Porath (President & CEO), Yuval Shezifi (CTO), and Pauliina Margolis (CMO & VP).

Name

Keystone Heart

Website

https://keystoneheart.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

11–50 employees

Short description

Keystone Heart is an Israeli medical device company developing cerebral embolic protection devices used during TAVR and other cardiovascular procedures to reduce stroke risk, selling primarily to hospital structural heart programs.

Ownership category

akta.pro rank

Product category

Cerebral Embolic Protection Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Thrombectomy, Embolic Protection & Stroke Intervention Devices (HLAHAFAJ)

akta.pro secondary industries

Structural Heart Valves (TAVR/SAVR) & Valve Repair (HLAHAFAB), Interventional Cardiology (PCI/Structural Heart) (HLAKABAB)

Keywords

• Cerebral embolic protection
• Cardiovascular medical devices
• TAVR procedure devices
• Stroke prevention devices
• Embolic protection systems

Headquarters

HQ city

Herzliya

HQ country

Israel

HQ region

Middle East

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Marketing or Sales, Others

Core offering

Keystone Heart develops and manufactures cerebral embolic protection medical devices used during cardiovascular procedures, including TAVR (Transcatheter Aortic Valve Replacement), intended to reduce the risk of peri-procedural stroke by capturing embolic debris. The company operates in the cerebral protection segment of the cardiovascular medical device market and expanded its portfolio through the 2020 acquisition of 510 Kardiac Devices.

Differentiator

Problem solved

Functional benefit

Products and services

• Cerebral embolic protection devices Devices used during cardiovascular procedures, including TAVR (Transcatheter Aortic Valve Replacement), designed to capture embolic debris and reduce the risk of peri-procedural stroke. Sold to hospitals and cardiac care providers.
• Cardiac devices (via 510 Kardiac Devices) Cardiac device products obtained through the acquisition of 510 Kardiac Devices on 2020-06-16, expanding Keystone Heart's cardiovascular portfolio beyond cerebral embolic protection.

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves2 records

Expansion highlights3 records

Broad incumbents

• Boston Scientific: Boston Scientific markets the Sentinel Cerebral Protection System, the leading cerebral embolic protection device for TAVR procedures — the most direct competitive product to Keystone Heart's offering. As a major incumbent cardiovascular device company, Boston Scientific competes head-to-head with Keystone Heart for hospital contracts and physician adoption in the same clinical specialty.
• Edwards Lifesciences: Edwards Lifesciences is the dominant TAVR valve manufacturer (Sapien platform) and a key customer-channel partner and indirect competitor to embolic protection players. While Edwards does not primarily sell cerebral protection devices, its installed base makes it a critical reference point for adoption and procedural volumes directly impacting Keystone Heart's market opportunity.
• Medtronic: Medtronic is a leading structural heart and TAVR player (Evolut platform) with broad cardiovascular device portfolio. As a major TAVR valve manufacturer and an integrated device company potentially evaluating or expanding into cerebral embolic protection, Medtronic is a comparable incumbent in the broader structural heart/cath lab ecosystem.
• Abbott Vascular: Abbott operates structural heart, vascular, and cardiovascular device franchises (including Portico TAVR). Comparable to Keystone Heart as a broad cardiovascular incumbent serving interventional cardiology and structural heart teams with potential strategic interest in cerebral embolic protection.

Emerging players

• Protembis: Protembis is developing the ProtEmbo cerebral protection system designed for use during TAVR and other left-sided structural heart procedures. It is a direct emerging competitor to Keystone Heart's cerebral embolic protection device, targeting the same clinical niche with a similar deflector-style filter concept.
• Emboline: Emboline has developed the Emboliner catheter, a total embolic protection device designed for transcatheter aortic valve replacement and other cardiovascular procedures. It overlaps with Keystone Heart on embolic protection technology, target indication (TAVR), and end-user base (interventional cardiologists and heart teams).
• InspireMD: InspireMD develops embolic prevention and stroke prevention systems including the CGuard carotid stent platform. Comparable as a smaller emerging player in the embolic protection / stroke prevention medical device space with similar regulatory and clinical-trial-driven go-to-market profile.

Regional players

• Venus Medtech: Venus Medtech is a leading Chinese structural heart company focused on TAVR and related devices across Asia-Pacific. Comparable to Keystone Heart through shared structural heart focus, TAVR exposure, and overlapping interest in embolic protection for transcatheter procedures across major geographic markets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks4 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/2768313

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Keystone Heart